CRES101 and CRES102 are novel and specific biotechologies for treatment of neurodegenerative disorders.
Precursor CRES101 (EFG) induces positive response in Experimentals models of Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
versus a reference corticoid derived treatment.
(luxol fast blue stained sections of spinal cord).
chronic inflammatory demyelinating polyneuropathy (CIDP) - Orphan disease
From a pathological and clinical standpoint, CIDP has numerous analogies with MS: progressive and relapsing forms of CIDP are also observed.
Guillain Barré Syndrome (GBS) - orphan disease
GBS is an acute form of CIDP and an immune condition, often following an infection.
Nerve lesions marked by demyelination are the pathological hallmarks.
Multiple Sclerosis progressive forms (ms) - rare disease
Myelin continually degrades leading to axon degeneration and neuronal death.
Neurodegeneration is responsible for the chronic disability and progression of MS.
Current treatments for MS rely on immunosuppression with little action, if not on neuroprotection: progressive forms are hardly treated.
Alzheimer’s is a neurodegenerative disease in which protein deposits form amyloid plaques and tau tangles in the brain: neurons stop functioning, lose connections and die; the brain shrinks dramatically.
The disease begins with memory impairment; evolution progressively leads to communication problems, addiction and eventually death.
There is no disease-modifying treatment. Only symptomatic treatments somehow delay progression.